Related Experiment Video

Updated: May 7, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.8K

Nirsevimab: A Review

Howard Balbi1

  • 1Department of Pediatrics, Good Samaritan University Hospital, West Islip, New York, USA.

Pediatric Allergy, Immunology, and Pulmonology
|March 14, 2024
PubMed

Insights

New RSV prevention tools offer hope for infants and older adults. Nirsevimab, a long-acting antibody, is recommended for infants, while vaccines are available for older adults and pregnant women.

Area of Science:

  • Pediatrics
  • Immunology
  • Public Health

Background:

  • Respiratory syncytial virus (RSV) is a leading cause of infant hospitalization in the U.S.
  • RSV causes severe lower respiratory tract infections across all age groups.
  • Recent advancements in 2023 have introduced novel prevention strategies.

Purpose of the Study:

  • To review the recent FDA approvals of new RSV prevention tools.
  • To highlight the role of nirsevimab, a monoclonal antibody, for infant protection.
  • To discuss recommendations for nirsevimab administration in infants and at-risk children.

Main Methods:

  • Review of FDA approvals and recommendations from ACIP and AAP.
  • Focus on nirsevimab (Beyfortus™) for RSV prevention in vulnerable populations.
  • Analysis of vaccine approvals for older adults and pregnant women.

Main Results:

  • FDA approved three new RSV prevention tools in 2023.
  • Nirsevimab (Beyfortus™) approved for infants and young children.
  • Vaccines (Arexvy™ and Abrysvo™) approved for adults 60+ and pregnant women.

Conclusions:

  • Nirsevimab is recommended for all infants under 8 months and high-risk children aged 8-19 months.
  • New RSV vaccines and monoclonal antibodies significantly advance prevention efforts.
  • These tools aim to reduce severe RSV disease and hospitalizations in infants and the elderly.

Keywords:
RSVmonoclonal antibodynirsevimabvaccine

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.5K
Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo07:33

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

1.8K

Related Concept Videos

Humoral Immune Responses01:36

Humoral Immune Responses

Overview
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Human Virome01:26

Human Virome

The human body harbors a vast and diverse viral community known as the human virome. The virome includes bacteriophages that infect bacteria, and eukaryotic viruses that infect human cells. Transient dietary and environmental viruses also contribute to this dynamic ecosystem. Estimates suggest the human body may contain on the order of 10¹³ viral particles, though abundance varies widely by body site and detection method.Comprehensive characterization of the virome has become possible only with...